Research Paper Volume 14, Issue 8 pp 3597—3606
Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
Figure 2. The BET inhibitor JQ1 suppresses KRAS mutant pancreatic cancer cells. (A) The structure of the BET inhibitor JQ1. (B) Fitting curve of cytostatic responses illustrated a decreasing concentration gradient of JQ1 treated with 7 KRAS mutant pancreatic cancer cell lines (AsPC-1, MIA PaCa-2, PANC-1, HuP-T4, HuP-T3, PSN1, and CFPAC-1).